For Portfolios & Trading
FREE SUPPORT 1-866-801-3359
Endologix Inc, China Cord Blood, Cyclacel Pharmaceuticals Inc, Synergy Pharmaceuticals Inc, Signal Genetics, Cesca Therapeutics Inc.
**Each Pool is built from the ground up using our in-house proprietary modeling techniques combined with serious investment valuation of each position allowing us to build, trade and execute a winning strategy in the most volatile of markets. Each Pool's portfolio is based on Modern Portfolio Theory (MPT), or mean-variance analysis. Our models use Monte Carlo Sampling to find the best fit for each Pool.The Pools are recalibrated every 30 days. Call us @ 1-866-801-3359, if you would like to discuss or speak with a trader on any of our Pool offerings or email Customer Service with your questions.
UCS Biotech/Pharma Pool- CURE 112
Maximum Pool Size: $25,000
Current Pool Size: $11,000
Liquidation date: 05/12/2017
Average Share Price of Positions in the Pool: $4.35
Net Asset Value Per Share: $1.05
Current Value of Pool: $10,066.36
Bid: $1.0066 Offer: $1.01
Last updated on: 6/28/2017
Pool Returns: -0.085%
Pool status: Closed As of 5/12/2011
Biotech stocks along with ETFs in the sector have generated large returns in 2016, producing double-digit gains which could help boost the returns of 401(k)s and IRAs.
Investors seeking to get greater yields or to increase diversification in their retirement portfolios should examine the health care sector as a hedge against